 |
Soluble complement receptor type 1 |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass |
| USA Market Approval | USA |
| USA Designation Date | 2000-03-06 00:00:00 |
| Sponsor | Avant Immunotherapeutics, Inc.;119 Fourth Ave.;Needham, Massachusetts, 02494 |
